Hoth Therapeutics Files 2024 Proxy Statement

TL;DR

Hoth Therapeutics DEF 14A filed. Annual meeting Aug 7. Vote your shares!

AI Summary

Hoth Therapeutics, Inc. filed its Definitive Proxy Statement (DEF 14A) on June 18, 2024, for its annual meeting of shareholders scheduled for August 7, 2024. The filing outlines the company's corporate governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine disclosures, but the specific proposals and outcomes of the shareholder meeting can significantly impact the company's future operations and stock performance.

Key Numbers

• 20240807 — Annual Meeting Date (Shareholders will vote on company matters on this date.)
• 20240618 — Filing Date (The date Hoth Therapeutics filed its definitive proxy statement.)

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• 20240807 (date) — Annual Meeting Date
• 20240618 (date) — Filing Date
• 001-38803 (dollar_amount) — SEC File Number

FAQ

From the Filing

0001213900-24-053502.txt : 20240618 0001213900-24-053502.hdr.sgml : 20240618 20240618060727 ACCESSION NUMBER: 0001213900-24-053502 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20240807 FILED AS OF DATE: 20240618 DATE AS OF CHANGE: 20240618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241050117 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 DEF 14A 1 ea0207116-def14a_hoththerap.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.14a-12 HOTH THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 HOTH THERAPEUTICS, INC. 590 Madison Ave., 21st Floor New York, NY 10022 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 7, 2024 To the Shareholders of Hoth Therapeutics, Inc.: The 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”) of Hoth Therapeutics, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”), will be held on Wednesday, August 7, 2024, at 12:00 p.m. Eastern Time. The 2024 Annual Meeting will be a completely virtual meeting which will be conducted via live webcast. You will be able to attend the 2024 Annual Meeting by visiting www.virtualshareholdermeeting.com/HOTH2024 . In addition to voting by submitting your proxy prior to the 2024 Annual Meeting, you also will be able to vote your shares electronically during the 2024 Annual Meeting. Further details regarding the virtual meeting are included in the accompanying proxy statement. At the 2024 Annual Meeting, the holders of our outstanding common stock will act on the following matters: 1. To elect members of the Company’s board directors (the “Board”) to serve for a one-year term to expire at the 2025 annual meeting of shareholders; 2. To ratify the appointment of WithumSmith+Brown, PC (“Withum”) as our independent registered public accounting firm for the fiscal year ending December 31, 2024; 3. To approve an amendment to the Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (the “2022 Plan”) to increase the number of shares of common stock reserved for issuance thereunder to 1,091,317 shares from 591,317 shares (the “Plan Amendment”); and 4. To transact such other business as may properly be brought before the 2024 Annual Meeting or any adjournment or postponement thereof. Our Board unanimously recommends that you vote: “ FOR ” the election of our Board’s director nominees (Proposal 1); “ FOR ” the ratification of the appointment of Withum as our independent registered public accounting firm for